Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

Recruiting now · Phase 2

Conditions studied: CD20-positive Acute Lymphoblastic Leukemia

In brief

A multicenter, prospective, randomized and controlled study to compare the efficacy and safety of obinutuzumab and rituximab in adult ALL patients with CD20 expression.Study population is 124 patients (62 in each study group).

Key facts

Study ID
NCT04920968
Run by
Maria Sklodowska-Curie National Research Institute of Oncology
People needed
124
Starts
2021-10-05
Expected to finish
2025-12-31
Last updated by the study team
2025-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.